PromarkerD was showcased at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, 16-20 September 2019 where Patia Europe and Proteomics International Head of Business Development Mr. Chuck Morrison met with diagnostic and pharmaceutical companies and Key Opinion Leaders from around the world to expand the global reach of PromarkerD. Mr. Chuck Morrison and Patia Europe were at Booth IZ.06.
PromarkerD is being commercialised by Patia Europe [ASX: 24 October 2018], with the Laboratory Developed Test (LDT) being offered through an expansion of the partnership with specialist mass spectrometry diagnostics firm Atturos, Ireland [ASX: 12 September 2019]. The exclusive licence agreement with Patia Europe for Spain is for two years and Proteomics International will receive a royalty on each test sold.
The European launch of PromarkerD is a pivotal milestone for Proteomics International providing a critical market platform to broaden the awareness of the test, potentially accelerating the execution of additional licensing transactions and jurisdictional launches.